GVW is a data management company specializing in the life sciences, while L7 has developed a technology platform designed to eliminate data and process silos in the life sciences. At MOTM 2022, Hendriks and Rangadass discussed their shared focus on the process life cycle, and the challenges of integrating datasets and bridging the gap between life sciences and healthcare data.

"We have to connect first before making it perfect. I think that the technology of L7 can play a massive role in it. I don't know anything else in this market that compares to that," Hendriks said.

Bridging gaps and making connections with data are especially important in the cell and gene therapy sector, the nature of which demands a shift in focus from final product to process.

"In cell and gene therapies, the actual process is the product," Rangadass explained.

Click on the video below to learn more.

Forge Biologics shares plans for growth at Meeting on the Med
Chief commercial officer John Maslowski and senior vice president of business development Magdalena Tyrpien of Forge Biologics spoke with ScienceBoard.net...

Cevec Pharmaceuticals CEO stresses challenges in producing AAV vectors
It will be a real challenge to produce sufficient quantities of gene therapy products, in particular when it comes to adeno-associated virus (AAV) vectors,...

Advances in gene therapy call for education, patient advocate says
Durhane Wong-Rieger, board chair of Rare Diseases International, spoke to ScienceBoard.net at the Cell & Gene Meeting on the Med last week in...

Investment continues in cell and gene sector, despite disruptions
Investment in the cell and gene therapy sector remains robust, despite the disruptions over the last several years due to the COVID-19 pandemic. That's...